Status:
COMPLETED
Effect of Liraglutide in Combination With Sulfonylurea (SU) on Blood Glucose Control in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
20+ years
Phase:
PHASE3
Brief Summary
This trial is conducted in Japan. The trial aims for comparison of the effect on glycaemic control of liraglutide in combination with sulphonylurea agent (SU) compared to SU monotherapy, as assessed b...
Eligibility Criteria
Inclusion
- Type 2 diabetes
- Diet/exercise therapy with sulfonylurea (SU) for at least eight weeks
- HbA1c greater than or equal to 7.0% and less than 10.0%
- BMI less than 35 kg/m2
Exclusion
- Treatment with insulin within the last 12 weeks
- Treatment with any drug that could interfere with the glucose level
- Any serious medical condition
- Females who are pregnant, have intention of becoming pregnant or are breastfeeding
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
264 Patients enrolled
Trial Details
Trial ID
NCT00395746
Start Date
October 1 2006
End Date
May 1 2008
Last Update
March 8 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Tokyo, Japan, 1000005